Humanized antibodies
US7320790B2 · kind B2 · utility
36Cited by
13References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 26, 2002 |
| Grant date | Jan 22, 2008 |
| Priority date | — |
| Expiry date | Aug 12, 2023 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.